Insider Cluster (3 insiders) ·Filed Jun 16, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago
Insider cluster: 2 insiders, $2.0M total
Actionable Insight • Neutral

The insider selling is immaterial in size and involves only directors, not C-suite. No bearish signal. Monitor for any future C-suite selling or a material increase in dollar volume before adjusting stance.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
LGND ▲ +13.32% at T+60d
NEUTRAL call ✓ call won +13.32% · α vs SPY +12.32% · entry $255.25 → $289.25
Entry anchored
Jun 15, 03:59 PM ET
via exchange tick
T+1d
+3.09%
call +3.09% · α +4.34%
$263.14
settled 4mo ago
T+5d
+9.48%
call +9.48% · α +11.71%
$279.44
settled 3mo ago
T+20d
+17.91%
call +17.91% · α +17.71%
$300.97
settled 3mo ago
T+60d
+13.32%
call +13.32% · α +12.32%
$289.25
settled 22d ago

Price Chart

Loading chart...

Executive Summary

Three directors sold a total of ~$1.95M in LGND shares over a 7-day window, representing only ~0.04% of the company's $5.1B market cap. All sellers are non-C-suite directors, and the sales are trivial relative to market cap, indicating routine portfolio diversification rather than informed selling.

Key Financial Metrics

Direction
selling
Total Value
$1.9M
Insiders
3

Key Facts

  • Total insider sales of ~$1.95M across 3 directors (Haas, Aryeh, Lamattina) from June 10-12, 2026.
  • Sales represent ~0.04% of LGND's $5.1B market cap — well below the 0.1% materiality threshold.
  • No C-suite executives (CEO, CFO, etc.) participated in the cluster; all sellers are directors.
  • Director Haas exercised derivative options (non-cash) before selling, a common pattern for tax planning.

Financial Impact

~$1.95M in open-market sales, negligible relative to $5.1B market cap

insider ownership

Risk Factors

  • None from this cluster; however, continued director selling at higher volumes could signal reduced confidence.
  • LGND's stock is near $250; any unexpected negative catalyst (e.g., pipeline setback) could amplify selling.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-LGND-1781572048043
10 reports for LGND
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +38.85%Apr 14, 2026
Filters
Rows
Reports for LGND — sortable, filterable
TypeNow
Sep 14, 2026
17d ago
Insider Cluster
NEUTRAL ★ 3/10
$276.98 $298.50▲ +7.77%▲ +5.66%$302.96 (+9.38%)
Aug 14, 2026
6w ago
Insider Cluster
NEUTRAL ★ 4/10
$291.77 $280.18▼ −3.97%▼ −2.78%$302.96 (+3.84%)
Aug 6, 2026
8w ago
8-K
BULLISH ★ 7/10
$300.14 $288.82▼ −3.77%▼ −4.98%$302.96 (+0.94%)
Jun 25, 2026
14w ago
8-K
MIXED ★ 6/10
$303.59 $319.55▲ +5.26%▲ +3.09%$302.96 (−0.21%)
Jun 18, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$274.88 $295.92▲ +7.65%▲ +9.32%$302.96 (+10.22%)
Jun 16, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$255.25 $279.44▲ +9.48%▲ +11.71%$302.96 (+18.69%)
Jun 12, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$253.25 $262.17▲ +3.52%▲ +4.91%$302.96 (+19.63%)
May 1, 2026
22w ago
Insider Cluster
NEUTRAL ★ 3/10
$227.44 $221.41▼ −2.65%▼ −5.00%$302.96 (+33.20%)
Apr 14, 2026
24w ago
Press Release
BULLISH ★ 8/10
$232.34 $226.67▼ −2.44%▼ −3.83%$302.96 (+30.40%)
Feb 26, 2026
31w ago
8-K
BULLISH ★ 8/10
$196.17 $206.27▲ +5.15%▲ +6.28%$302.96 (+54.44%)
Showing 10 of 10

US Market Status

Market Closed — Opens Mon (64h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 16, 2026